Expert Ratings
Easily search Stocks, Mutual Funds, eBooks, Articles and Videos
Track the companies of Group.
| Sales Growth | Profit Growth | Expense Growth | Stock Price CAGR |
|---|---|---|---|
Presentation & Earning Calls |
Annual Reports |
Credit Rating |
|---|---|---|
|
|
|
|
Marksans Pharma, incorporated in 1992, was a wholly-owned subsidiary of Glenmark Pharmaceuticals. It became a separate entity in March 2003 and the name was changed to Marksans Pharma in 2005.
Currently the company has presence in Active Pharmaceuticals Ingredients (APIs), formulations and biopharmaceuticals. It is also actively engaged in research and development and offers contract research and manufacturing services (CRAMS) to global pharmaceutical companies.
The company, engaged in production of prescription drugs, caters in areas like oncology, gastroenterology, antidiabetic, cardiovascular, pain management, gynaecology and others.
The company's plants have been built as per USFDA guidelines and have received approval from various health authorities namely TGA (
Marksans Pharma acquired Relonchem, a leading
Marksans Pharma exports its products to markets in Europe, Latin America, Africa and
In 2010 Company entered into a Business Transfer Agreement with Kores (India) Limited
Business area
Research and Development- The company’s R&D centre is situated in
Formulation- This division is engaged in manufacturing of tablets, non-sterile liquids, ointments and powder products. The company owns one of the biggest manufacturing facility for soft gelatin in
APIs- Marksans' two APIs manufacturing units are located in Pune. The present manufacturing capacity of 1140 TPA that comprises of 600 TPA Quinolones, 360 TPA Ranitidine, and 180 others.
CRAMS- The company has alliances with the top 8 MNC generic companies for contract manufacturing of 30 generic products for the European markets. It has entered into licensing agreements with numerous companies for development and supply of products for 7-10 years.
Milestones
This ratio is already added in the table
Comment